Data

A randomised phase III trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A early breast cancer (ANZ 1601/BIG 16-02: EXPERT).

Breast Cancer Trials (BCT)

Dataset description

THIS DATASET IS NOT YET AVAILABLE FOR SHARING. Dataset of around 1000 luminal A early breast cancer patients in a randomised phase III trial. Female patients aged >= 50 years, histologically confirmed invasive breast carcinoma <= 2 cm, grade 1 or 2, ER/PR positive, HER2 negative, primary tumour characterised by Prosigna (PAM50) assay as Luminal A intrinsic subtype and risk of recurrence score <= 60. Treated by breast conserving surgery with negative margins for invasive carcinoma and any associated ductal carcinoma in situ (DCIS). Negative axillary nodal status determined by sentinel node biopsy or axillary dissection. Eligible for and willing to have adjuvant endocrine therapy. Not planned for adjuvant chemotherapy or biologic anti-cancer therapy. Participants are randomised to ARM A: RT + endocrine therapy or ARM B: no RT (endocrine therapy only). Primary indpoint is local recurrence free interval. Patient Reported Outcomes: data is available from 433 English-speaking patients from PROM measuring Fear of Cancer Recurrence (FCR Inventory), Convenience of Care (study specific), Fatigue (Brief Fatigue Inventory), Endocrine Therapy (19 endocrine-symptom items from the FACT-ES), Anxiety and Depression (Hospital Anxiety and Depression Scale), QALY (EQ-5D-5L). A health economic analysis will also be performed. Demographic data has been collected Age and Race/ethnicity.

Date Information

Issued from 2028
Click to explore relationships graph
 

Source Study

Purpose:
Not available
Phase:
Not available
Trial acronym

Not available

Trial ID

NCT02889874

Funding

Not available

Scientific enquiries

Brief Summary

This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype defined using the Prosigna (PAM50) Assay.

Key Inclusion Criteria

Inclusion Criteria: for registration in the study: 1. Female patients aged = 50 years of any menopausal status. 2. Primary tumour characteristics as assessed by conventional histopathology: * Unifocal histologically confirmed invasive breast carcinoma * Maximum microscopic size =2 cm * Grade 1 or 2 histology * ER and PR positive in =10% of tumour cells in either the biopsy or breast conserving surgical specimen * HER2 negative on IHC (score 0 or 1+) or in situ hybridisation (ERBB2-amplification .... Read more

Key Exclusion Criteria
Can healthy volunteers participate?

No

Population

Sample Size    Not Available

Min. age    50 Years

Max. age    N/A

Sex    Female

Condition category    Radiation therapy , breast cancer , non-inferiority , omission

Condition code    Early Stage Breast Carcinoma

Intervention

Intervention code Treatment: Other - Omission of radiation therapy

A: Radiation Therapy & endocrine therapy No intervention Patients randomized to Arm A will receive standard radiation therapy and adjuvant endocrine therapy (standard of care). B: No Radiation Therapy (ET only) Experimental Patients randomized to Arm B will not receive radiation therapy (omission of radiation therapy) and receive adjuvant endocrine therapy only. Treatment: Other: Omission of radiation therapy Omission of radiation therapy (adjuvant endocrine therapy only).

Comparison

Control group Not available

Comparison not available.

Outcomes

Not Available

The data-sharing statement for this study is currently unavailable.

Source study information is derived from the ClinicalTrials.gov. For more information, please see ClinicalTrials.gov

How is Heath Data Australia supporting health research?

To assist secondary data users in understanding the real-world impact of health and medical research data sharing, the Australian Research Data Commons (ARDC) has created an online guide that outlines a theoretical framework for four key data reuse scenarios. This practical guide was extracted from research papers, and consultation with stakeholders and the research community.

Read the guide

How to access data via Health Data Australia

With Health Data Australia, researchers can explore descriptions of data from our publishing partners, identify relevant datasets, and request access. These requests will then be forwarded to the data owner for review.

To start requesting data, simply login with your AAF account.

Learn more